SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Background: The clinical application of EGFR tyrosine kinase inhibitors is always accompanied by inevitable drug resistance. However, the mechanism remains elusive. In the present study, we investigate the involvement of MAPK/SREBP1 pathway in NSCLC gefitinib resistance and evaluate the synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Zhenzhen, Wang, Kai, Chen, Qiufang, Zheng, Xiulan, Song, Zhengyu, Ding, Xuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930422/
https://www.ncbi.nlm.nih.gov/pubmed/31897229
http://dx.doi.org/10.7150/jca.32989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930422/
https://www.ncbi.nlm.nih.gov/pubmed/31897229
http://dx.doi.org/10.7150/jca.32989

Ejemplares similares